1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Synlab AG

Synlab AG

SYAB.DE
Synlab AGDE flagDeutsche Börse
11.06
EUR
-0.02
- -
2.43BMarket Cap
Synlab AG
SYAB.DE
(Deutsche Börse)

Recent

price

11.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2020
2021
2022
2023
TTM
FRC
13.11
17.5
14.67
11.99
11.52
Revenue per Share
1.29
2.9
0.68
0.42
0.39
Basic EPS, GAAP
2.13
4.03
2.13
1.08
1.3
Free Cash Flow per Basic Share
0.01
0.01
0.36
0.35
- -
Dividend per Share
-1.55
-7.19
-2.69
-2.62
-2.43
Book Value per Share
-8.62
-4.23
-3.27
-2.09
-1.87
Tangible Book Value per Share
200
215
222
220
227
Basic Weighted Avg Shares
2,621
3,765
3,251
2,635
2,615
Sales/Revenue/Turnover
17.19
25.11
13.98
5.43
5.8
Operating Margin (%)
341
265
514
364
360
Depreciation Expense
258
625
151
92
89
Net Income, GAAP
69.71
24.24
46.1
35
35.52
Effective Tax Rate (%)
9.83
16.59
4.64
3.5
3.42
Profit Margin (%)
854
357
440
106
166
Working Capital
3,019
1,900
1,966
1,403
1,388
LT Debt
1,204
2,256
2,333
2,338
2,370
Total Equity
- -
16.34
5.53
2.23
2.35
Return on Invested Capital (%)
- -
43.5
18.26
12.93
13.22
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'23
Dec'23
Mar'24
ST Debt
152
157
158
LT Borrowings
1,099
903
904
LT Finance Leases
493
500
483
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
220
220
220
Market Capitalization
2,166
2,451
2,486

Working Capital

FRC

•

in mil. unless spec.
Sep'23
Dec'23
Mar'24
Total Current Assets
1,054
789
860
Cash, Cash Equivalents & STI
469
265
300
Accounts Receivable, Net
412
398
438
Inventories
69
65
63
Total Current Liabilities
728
683
694
Payables & Accruals
- -
- -
- -
ST Debt
152
157
158
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
0.21%
Free Cash Flow
- -
- -
-49.74%
Net Income, GAAP
- -
- -
-38.77%
Sales/Revenue/Turnover
- -
- -
-18.93%
Total Cash Common Dividend
- -
- -
-2.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1,061
790
698
701
3,251
2023
702
670
617
645
2,635
2024
682
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
0.97
- -
- -
- -
0.68
2023
0.13
- -
- -
- -
0.42
2024
0.11
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
0.01
- -
- -
- -
0.36
2023
- -
- -
- -
- -
0.35
2024
- -
- -
- -
- -
- -
Similar Companies
IQVIA Holdings Inc. (0JDM.L)
Eurofins-Cerep S.A. (ALECR.PA)
Myriad Genetics, Inc. (MYD.DE)
ANGLE plc (AGL.L)
Illumina, Inc. (0J8Z.L)
Tecan Group AG (0QLN.L)
Business
SYNLAB AG (SYAB.DE) is Europe's leading provider of medical diagnostic services and specialty testing, offering a comprehensive portfolio of laboratory diagnostics including clinical chemistry, haematology, coagulation, microbiology, serology, immunology, genetics, molecular biology, pathology, cytology, endocrinology, maternity care and veterinary diagnostics to patients, practising doctors, hospitals, clinics, governments and corporates; the company operates over 350 laboratories, more than 1,800 blood collection points and partners with over 700 hospitals across more than 20 countries on four continents. Founded in 1998 and headquartered in Munich, Germany, SYNLAB conducts approximately 600 million tests annually through a network of over 2,000 medical experts and 24,000 employees. Recent developments include Cinven's agreement in October 2024 to acquire Elliott Advisors' 10% stake with a squeeze-out to follow in early 2025, the sale of a 15% minority stake to strategic investor Labcorp in September 2024 for about EUR140 million, expanded investments in Italy with a flagship Medical Centre opening in October 2025 and further diagnostics enhancements, eight acquisitions in 2023 totalling EUR90 million primarily in Germany, Italy, Belgium and France, and divestiture of operations in Romania, Turkey, Cyprus, Slovenia, Croatia and North Macedonia to Medicover in April 2025 for EUR71.3 million.